vTv Therapeutics (VTVT) Stock Forecast, Price Target & Predictions
VTVT Stock Forecast
vTv Therapeutics stock forecast is as follows: a rating consensus of 'Buy', based on 1 wall street analysts offering a 1-year stock forecast.
VTVT Analyst Ratings
According to 1 Wall Street analysts, vTv Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for VTVT stock is 0 'Strong Buy' (0.00%), 1 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Feb 18, 2022 | Cantor Fitzgerald | - | Overweight | Initialise |
vTv Therapeutics's last stock rating was published by Cantor Fitzgerald on Feb 18, 2022. The company Initialise its VTVT rating from "null" to "Overweight".
vTv Therapeutics Financial Forecast
vTv Therapeutics Revenue Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Dec 22 | Sep 22 | Jul 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Dec 19 | Sep 19 | Jun 19 | Dec 18 | Sep 18 | Jun 18 | Mar 18 | Dec 17 | Sep 17 | Jun 17 | Mar 17 | Dec 16 | Sep 16 | Jun 16 | Mar 16 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | $9.00K | - | - | $4.00K | $3.00M | $9.00K | $987.00K | $6.40M | $7.00K | - | $7.00K | $8.00K | $1.83M | $4.52M | $3.38M | $2.47M | $2.06M | $233.00K | $15.00K | $13.00K | $30.00K | $38.00K | $38.00K | $182.00K | $376.00K |
| Avg Forecast | - | - | - | $1.00M | - | $3.09M | $250.00K | $8.41K | $500.00K | $1.30M | $1.00M | $800.00K | $3.30M | $21.00K | $10.29K | $1.25M | $1.69M | $1.63M | $3.32M | $6.75M | $1.99M | $2.34M | $222.41K | $15.79K | $13.63K | $30.00K | $25.33K | $42.63K | $329.15K | $859.43K |
| High Forecast | - | - | - | $1.00M | - | $3.70M | $250.00K | $10.10K | $500.00K | $1.30M | $1.00M | $800.00K | $3.30M | $25.20K | $12.34K | $1.25M | $1.69M | $1.63M | $3.98M | $8.10M | $2.39M | $2.81M | $266.89K | $18.95K | $16.36K | $36.00K | $30.40K | $51.16K | $394.98K | $1.03M |
| Low Forecast | - | - | - | $1.00M | - | $2.47M | $250.00K | $6.73K | $500.00K | $1.30M | $1.00M | $800.00K | $3.30M | $16.80K | $8.23K | $1.25M | $1.69M | $1.63M | $2.65M | $5.40M | $1.60M | $1.87M | $177.93K | $12.63K | $10.91K | $24.00K | $20.27K | $34.11K | $263.32K | $687.54K |
| # Analysts | - | - | - | - | 10 | 12 | - | 12 | 6 | 6 | 10 | 10 | 10 | 20 | 7 | 2 | 7 | 7 | 16 | 8 | 13 | 14 | 8 | 14 | 16 | 9 | 19 | 13 | 9 | 8 |
| Surprise % | - | - | - | - | - | 0.00% | - | - | 0.01% | 2.31% | 0.01% | 1.23% | 1.94% | 0.33% | - | 0.01% | 0.00% | 1.12% | 1.36% | 0.50% | 1.24% | 0.88% | 1.05% | 0.95% | 0.95% | 1.00% | 1.50% | 0.89% | 0.55% | 0.44% |
vTv Therapeutics's average Quarter revenue forecast for Dec 23 based on 10 analysts is -, with a low forecast of -, and a high forecast of -. VTVT's average Quarter revenue forecast represents a -100.00% decrease compared to the company's last Quarter revenue of $9.00K (Dec 22).
vTv Therapeutics EBITDA Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Dec 22 | Sep 22 | Jul 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Dec 19 | Sep 19 | Jun 19 | Dec 18 | Sep 18 | Jun 18 | Mar 18 | Dec 17 | Sep 17 | Jun 17 | Mar 17 | Dec 16 | Sep 16 | Jun 16 | Mar 16 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 10 | 12 | - | 12 | 6 | 6 | 10 | 10 | 10 | 20 | 7 | 2 | 7 | 7 | 16 | 8 | 13 | 14 | 8 | 14 | 16 | 9 | 19 | 13 | 9 | 8 |
| EBITDA | - | - | - | - | $-4.68M | $-6.08M | $-5.44M | - | $5.74M | $-959.00K | $-586.00K | $-4.20M | $1.22M | $-1.27M | $-3.12M | $-4.10M | $-3.20M | $-2.26M | $-241.00K | $56.00K | $-1.96M | $-2.06M | $-2.61M | $-2.75M | $-3.08M | $-3.61M | $-3.60M | $-3.92M | $-4.39M | $-3.77M |
| Avg Forecast | - | - | - | $-600.00K | - | $2.45M | $-1.38M | $-915.79K | $-300.00K | $-1.48M | $-979.46K | $-2.80M | $2.62M | $-1.91M | $-5.80M | $-2.51M | $-2.61M | $-2.26M | $-153.36K | $75.60K | $-1.49M | $-2.30M | $-2.49M | $-2.89M | $-3.22M | $-3.61M | $-1.98M | $-4.35M | $-5.71M | $-5.31M |
| High Forecast | - | - | - | $-600.00K | - | $2.94M | $-1.11M | $-732.63K | $-300.00K | $-1.18M | $-783.57K | $-2.24M | $3.15M | $-1.53M | $-4.64M | $-2.00M | $-2.09M | $-1.81M | $-122.69K | $90.72K | $-1.19M | $-1.84M | $-1.99M | $-2.31M | $-2.58M | $-2.89M | $-1.59M | $-3.48M | $-4.57M | $-4.24M |
| Low Forecast | - | - | - | $-600.00K | - | $1.96M | $-1.66M | $-1.10M | $-300.00K | $-1.78M | $-1.18M | $-3.36M | $2.10M | $-2.29M | $-6.96M | $-3.01M | $-3.14M | $-2.71M | $-184.04K | $60.48K | $-1.79M | $-2.76M | $-2.99M | $-3.47M | $-3.87M | $-4.33M | $-2.38M | $-5.22M | $-6.86M | $-6.37M |
| Surprise % | - | - | - | - | - | -2.48% | 3.93% | - | -19.12% | 0.65% | 0.60% | 1.50% | 0.46% | 0.67% | 0.54% | 1.64% | 1.22% | 1.00% | 1.57% | 0.74% | 1.32% | 0.89% | 1.05% | 0.95% | 0.96% | 1.00% | 1.82% | 0.90% | 0.77% | 0.71% |
12 analysts predict VTVT's average Quarter EBITDA for Jul 22 to be $-915.79K, with a high of $-732.63K and a low of $-1.10M. This is -115.97% lower than vTv Therapeutics's previous annual EBITDA (Dec 21) of $5.74M.
vTv Therapeutics Net Income Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Dec 22 | Sep 22 | Jul 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Dec 19 | Sep 19 | Jun 19 | Dec 18 | Sep 18 | Jun 18 | Mar 18 | Dec 17 | Sep 17 | Jun 17 | Mar 17 | Dec 16 | Sep 16 | Jun 16 | Mar 16 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 10 | 12 | - | 12 | 6 | 6 | 10 | 10 | 10 | 20 | 7 | 2 | 7 | 7 | 16 | 8 | 13 | 14 | 8 | 14 | 16 | 9 | 19 | 13 | 9 | 8 |
| Net Income | - | - | - | - | $-3.48M | $-5.89M | $-4.26M | - | $8.23M | $-1.09M | $-608.00K | $-4.24M | $1.13M | $-1.53M | $-3.37M | $-4.40M | $-3.61M | $-2.88M | $-1.09M | $-796.00K | $-3.07M | $-2.95M | $-4.31M | $-3.65M | $-3.96M | $-4.22M | $-4.05M | $-3.99M | $-4.46M | $-3.85M |
| Avg Forecast | $-20.49M | $-23.05M | $-20.49M | $-13.25M | $-5.84M | $2.27M | $-1.57M | $-950.17K | $-5.28M | $-1.68M | $-1.02M | $-2.83M | $2.43M | $-2.30M | $-4.12M | $-2.69M | $-2.95M | $-2.88M | $-694.27K | $-1.07M | $-2.33M | $-3.30M | $-4.11M | $-3.83M | $-4.15M | $-4.22M | $-2.23M | $-4.43M | $-5.80M | $-5.42M |
| High Forecast | $-20.49M | $-23.05M | $-20.49M | $-13.25M | $-5.84M | $2.73M | $-1.25M | $-760.14K | $-5.28M | $-1.34M | $-812.98K | $-2.26M | $2.92M | $-1.84M | $-3.29M | $-2.15M | $-2.36M | $-2.31M | $-555.42K | $-859.68K | $-1.87M | $-2.64M | $-3.28M | $-3.07M | $-3.32M | $-3.38M | $-1.78M | $-3.54M | $-4.64M | $-4.33M |
| Low Forecast | $-20.49M | $-23.05M | $-20.49M | $-13.25M | $-5.84M | $1.82M | $-1.88M | $-1.14M | $-5.28M | $-2.01M | $-1.22M | $-3.39M | $1.95M | $-2.76M | $-4.94M | $-3.23M | $-3.54M | $-3.46M | $-833.13K | $-1.29M | $-2.80M | $-3.96M | $-4.93M | $-4.60M | $-4.98M | $-5.06M | $-2.67M | $-5.31M | $-6.97M | $-6.50M |
| Surprise % | - | - | - | - | 0.60% | -2.59% | 2.72% | - | -1.56% | 0.65% | 0.60% | 1.50% | 0.46% | 0.67% | 0.82% | 1.64% | 1.22% | 1.00% | 1.57% | 0.74% | 1.32% | 0.89% | 1.05% | 0.95% | 0.96% | 1.00% | 1.82% | 0.90% | 0.77% | 0.71% |
vTv Therapeutics's average Quarter net income forecast for Jul 22 is $-950.17K, with a range of $-1.14M to $-760.14K. VTVT's average Quarter net income forecast represents a -111.54% decrease compared to the company's last Quarter net income of $8.23M (Dec 21).
vTv Therapeutics SG&A Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Dec 22 | Sep 22 | Jul 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Dec 19 | Sep 19 | Jun 19 | Dec 18 | Sep 18 | Jun 18 | Mar 18 | Dec 17 | Sep 17 | Jun 17 | Mar 17 | Dec 16 | Sep 16 | Jun 16 | Mar 16 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 10 | 12 | - | 12 | 6 | 6 | 10 | 10 | 10 | 20 | 7 | 2 | 7 | 7 | 16 | 8 | 13 | 14 | 8 | 14 | 16 | 9 | 19 | 13 | 9 | 8 |
| SG&A | - | - | - | - | $2.57M | $2.39M | $2.63M | - | $-6.61M | $2.22M | $2.24M | $2.16M | $2.04M | $1.07M | $1.70M | $1.99M | $1.77M | $2.39M | $2.07M | $2.16M | $2.74M | $2.25M | $2.94M | $2.57M | $3.00M | $2.82M | $2.25M | $2.40M | $2.67M | $2.58M |
| Avg Forecast | - | - | - | $2.87M | - | $8.85M | $717.36K | $24.15K | $1.43M | $3.73M | $2.87M | $2.30M | $9.47M | $60.26K | $29.51K | $1.22M | $1.45M | $4.66M | $1.32M | $2.91M | $5.72M | $6.71M | $638.18K | $45.30K | $39.12K | $86.08K | $72.69K | $122.33K | $944.47K | $2.47M |
| High Forecast | - | - | - | $2.87M | - | $10.62M | $717.36K | $28.98K | $1.43M | $3.73M | $2.87M | $2.30M | $9.47M | $72.31K | $35.41K | $1.46M | $1.74M | $4.66M | $1.58M | $3.50M | $6.87M | $8.05M | $765.82K | $54.36K | $46.94K | $103.30K | $87.22K | $146.80K | $1.13M | $2.96M |
| Low Forecast | - | - | - | $2.87M | - | $7.08M | $717.36K | $19.32K | $1.43M | $3.73M | $2.87M | $2.30M | $9.47M | $48.21K | $23.61K | $972.40K | $1.16M | $4.66M | $1.06M | $2.33M | $4.58M | $5.37M | $510.55K | $36.24K | $31.29K | $68.87K | $58.15K | $97.86K | $755.57K | $1.97M |
| Surprise % | - | - | - | - | - | 0.27% | 3.67% | - | -4.61% | 0.60% | 0.78% | 0.94% | 0.21% | 17.77% | 57.43% | 1.64% | 1.22% | 0.51% | 1.57% | 0.74% | 0.48% | 0.34% | 4.60% | 56.66% | 76.81% | 32.81% | 30.98% | 19.63% | 2.83% | 1.05% |
vTv Therapeutics's average Quarter SG&A projection for Mar 24 is $2.87M, based on 0 Wall Street analysts, with a range of $2.87M to $2.87M. The forecast indicates a 11.69% rise compared to VTVT last annual SG&A of $2.57M (Dec 23).
vTv Therapeutics EPS Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Dec 22 | Sep 22 | Jul 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Dec 19 | Sep 19 | Jun 19 | Dec 18 | Sep 18 | Jun 18 | Mar 18 | Dec 17 | Sep 17 | Jun 17 | Mar 17 | Dec 16 | Sep 16 | Jun 16 | Mar 16 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 10 | 12 | - | 12 | 6 | 6 | 10 | 10 | 10 | 20 | 7 | 2 | 7 | 7 | 16 | 8 | 13 | 14 | 8 | 14 | 16 | 9 | 19 | 13 | 9 | 8 |
| EPS | - | - | - | - | $-1.67 | $-0.07 | $-0.05 | - | $0.12 | $-0.02 | $-0.01 | $-0.08 | $0.02 | $-0.03 | $-0.07 | $-0.13 | $-0.13 | $-0.10 | $-0.06 | $-0.06 | $-0.31 | $-0.30 | $-0.44 | $-0.38 | $-0.41 | $-0.44 | $-0.42 | $-0.41 | $-0.47 | $-0.42 |
| Avg Forecast | $-3.20 | $-3.60 | $-3.20 | $-3.20 | $-2.80 | $-2.53 | $-1.73 | $-3.60 | $-2.53 | $-2.60 | $-2.80 | $-2.40 | $-2.20 | $-4.20 | $-3.80 | $-3.80 | $-4.40 | $-4.20 | $-0.07 | $-0.16 | $-0.19 | $-0.38 | $-0.40 | $-0.42 | $-0.45 | $-0.44 | $-0.15 | $-0.51 | $-1.11 | $-1.35 |
| High Forecast | $-3.20 | $-3.60 | $-3.20 | $-3.20 | $-2.80 | $-2.53 | $-1.73 | $-3.60 | $-2.53 | $-2.60 | $-2.80 | $-2.40 | $-2.20 | $-4.20 | $-3.80 | $-3.80 | $-4.40 | $-4.20 | $-0.06 | $-0.13 | $-0.15 | $-0.30 | $-0.32 | $-0.34 | $-0.36 | $-0.35 | $-0.12 | $-0.41 | $-0.89 | $-1.08 |
| Low Forecast | $-3.20 | $-3.60 | $-3.20 | $-3.20 | $-2.80 | $-2.53 | $-1.73 | $-3.60 | $-2.53 | $-2.60 | $-2.80 | $-2.40 | $-2.20 | $-4.20 | $-3.80 | $-3.80 | $-4.40 | $-4.20 | $-0.08 | $-0.19 | $-0.23 | $-0.46 | $-0.48 | $-0.50 | $-0.54 | $-0.53 | $-0.18 | $-0.61 | $-1.33 | $-1.62 |
| Surprise % | - | - | - | - | 0.60% | 0.03% | 0.03% | - | -0.05% | 0.01% | 0.00% | 0.03% | -0.01% | 0.01% | 0.02% | 0.03% | 0.03% | 0.02% | 0.88% | 0.38% | 1.63% | 0.79% | 1.10% | 0.90% | 0.91% | 1.00% | 2.80% | 0.80% | 0.42% | 0.31% |
According to 12 Wall Street analysts, vTv Therapeutics's projected average Quarter EPS for Jul 22 is $-3.60, with a low estimate of $-3.60 and a high estimate of $-3.60. This represents a -3100.00% decrease compared to VTVT previous annual EPS of $0.12 (Dec 21).
vTv Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| EFTR | eFFECTOR Therapeutics | $0.05 | $5.50 | 10900.00% | Buy |
| ELEV | Elevation Oncology | $0.61 | $9.00 | 1375.41% | Buy |
| KRON | Kronos Bio | $0.95 | $7.63 | 703.16% | Buy |
| IMMX | Immix Biopharma | $1.86 | $7.00 | 276.34% | Buy |
| GOVX | GeoVax Labs | $2.84 | $8.00 | 181.69% | Buy |
| EWTX | Edgewise Therapeutics | $18.83 | $48.00 | 154.91% | Buy |
| PYXS | Pyxis Oncology | $3.78 | $9.00 | 138.10% | Buy |
| ERAS | Erasca | $2.97 | $7.00 | 135.69% | Buy |
| CCCC | C4 Therapeutics | $6.44 | $11.33 | 75.93% | Hold |
| ZURA | Zura Bio | $3.70 | $5.00 | 35.14% | Buy |
| VTVT | vTv Therapeutics | $14.26 | $5.00 | -64.94% | Buy |
VTVT Forecast FAQ
Is vTv Therapeutics a good buy?
Yes, according to 1 Wall Street analysts, vTv Therapeutics (VTVT) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 100.00% of VTVT's total ratings.
What are vTv Therapeutics's analysts' financial forecasts?
vTv Therapeutics's analysts financial forecasts for the fiscal year (Dec 2023) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-5.838M (high $-5.838M, low $-5.838M), average SG&A $0 (high $0, low $0), and average EPS is $-2.8 (high $-2.8, low $-2.8). VTVT's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $1M (high $1M, low $1M), average EBITDA is $-600K (high $-600K, low $-600K), average net income is $-77.287M (high $-77.287M, low $-77.287M), average SG&A $2.87M (high $2.87M, low $2.87M), and average EPS is $-13.2 (high $-13.2, low $-13.2).
Did the VTVT's actual financial results beat the analysts' financial forecasts?
Based on vTv Therapeutics's last annual report (Dec 2022), the company's revenue was $2.02M, which missed the average analysts forecast of $3.34M by -39.65%. Apple's EBITDA was $-24.858M, missing the average prediction of $154.6K by -16179.23%. The company's net income was $-25.073M, beating the average estimation of $-244K by 10168.33%. Apple's SG&A was $12.2M, beating the average forecast of $9.6M by 27.16%. Lastly, the company's EPS was $-0.53, missing the average prediction of $-7.867 by -93.26%. In terms of the last quarterly report (Dec 2022), vTv Therapeutics's revenue was $9K, missing the average analysts' forecast of $3.09M by -99.71%. The company's EBITDA was $-6.084M, missing the average prediction of $2.45M by -347.94%. vTv Therapeutics's net income was $-5.89M, missing the average estimation of $2.27M by -359.02%. The company's SG&A was $2.39M, missing the average forecast of $8.85M by -73.03%. Lastly, the company's EPS was $-0.0723, missing the average prediction of $-2.533 by -97.15%